Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 8:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ccRCC Clear all
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer), Non Clear Cell Renal Cell Carcinoma (nccRCC)
Interventions
Darlifarnib, Cabozantinib, Adagrasib
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced May 21, 2026, 8:04 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasm, Renal Carcinoma
Interventions
Casdatifan, Zimberelimab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced May 21, 2026, 8:04 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced May 21, 2026, 8:04 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Interventions
ALLO-316, ALLO-647, Fludarabine, Cyclophosphamide
Genetic · Biological · Drug
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced May 21, 2026, 8:04 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Neoplasms
Interventions
Remzistotug, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
San Francisco, California • Charlotte, North Carolina • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced May 21, 2026, 8:04 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Sitravatinib, Nivolumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced May 21, 2026, 8:04 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Axitinib
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Omaha, Nebraska • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced May 21, 2026, 8:04 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic, ccRCC, VHL-Associated Clear Cell Renal Cell Carcinoma, VHL-Associated Renal Cell Carcinoma, Kidney Cancer Metastatic, Kidney Cancers
Interventions
NEO-811
Drug
Lead sponsor
Neomorph, Inc
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
San Diego, California • Grand Rapids, Michigan • Lake Success, New York + 5 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 8:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
Interventions
Selenomethionine (SLM), Axitinib
Drug
Lead sponsor
Mohammed Milhem
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 21, 2026, 8:04 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
89Zr-girentuximab
Diagnostic Test
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced May 21, 2026, 8:04 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
Interventions
REGN10597, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • North Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 21, 2026, 8:04 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence
Interventions
AB-2100
Biological
Lead sponsor
Arsenal Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Phoenix, Arizona • Duarte, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced May 21, 2026, 8:04 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
VHL Gene Mutation, VHL, VHL Syndrome, VHL Gene Inactivation, Von Hippel, Von Hippel-Lindau Disease, Von Hippel's Disease, Von Hippel-Lindau Syndrome, Modifiers of, Clear Cell Renal Cell Carcinoma, Clear Cell RCC, ccRCC
Interventions
MK-3795
Drug
Lead sponsor
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced May 21, 2026, 8:04 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab, Steriotactic radiation therapy
Drug · Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced May 21, 2026, 8:04 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumors, Hematologic Malignancies
Interventions
INCA036873
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Duarte, California • La Jolla, California • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 21, 2026, 8:04 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC), Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions
Fianlimab, Ipilimumab, Nivolumab, Cemiplimab
Drug
Lead sponsor
Brian Rini
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 8:04 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer, Non Small Cell Lung Cancer, Transitional Cell Carcinoma of the Bladder, Other Solid Tumors, Clear Cell Renal Cell Carcinoma
Interventions
HC-7366
Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
La Jolla, California • Aurora, Colorado • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced May 21, 2026, 8:04 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v7, Unresectable Renal Cell Carcinoma
Interventions
Ascorbic Acid, Pazopanib Hydrochloride
Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Peoria, Illinois • Urbana, Illinois • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced May 21, 2026, 8:04 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cancer
Interventions
SRK-181, anti-PD-(L)1 antibody therapy
Biological
Lead sponsor
Scholar Rock, Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Fullerton, California • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced May 21, 2026, 8:04 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
GAG score
Diagnostic Test
Lead sponsor
Elypta
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced May 21, 2026, 8:04 PM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder, Kidney Cancer, Clear Cell Renal Cell Cancer (ccRCC), Colorectal Cancer, MSI-H Colorectal Cancer, DMMR Colorectal Cancer, Head and Neck Cancer (H&N), Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Liver Cancer, Hepatocellular Carcinoma (HCC), Lung Cancer (NSCLC), NSCLC (Non-small Cell Lung Cancer), Skin Cancer, Cutaneous Melanoma, Endometrial Cancer, Solid Tumor Cancer
Interventions
Core Needle Biopsy, Forceps Biopsy, Punch Biopsy
Procedure
Lead sponsor
Elephas
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Little Rock, Arkansas • Salinas, California • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 21, 2026, 8:04 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Nivolumab and rHuPH20, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Buffalo, New York • West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced May 21, 2026, 8:04 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumor
Interventions
Single Injection of IVS-3001- Anti - HLA-G CAR-T cells, Fludarabine phosphate, Cyclophosphamide, leukapheresis
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced May 21, 2026, 8:04 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
ADI-270, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Adicet Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced May 21, 2026, 8:04 PM EDT